Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction
Top Cited Papers
- 16 March 2020
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 75 (11), 1281-1295
- https://doi.org/10.1016/j.jacc.2019.12.069
Abstract
No abstract availableFunding Information
- National Institutes of Health
- Bristol-Myers Squibb
This publication has 28 references indexed in Scilit:
- Growth Differentiation Factor-15 Is a Useful Prognostic Marker in Patients With Heart Failure With Preserved Ejection FractionCanadian Journal of Cardiology, 2014
- A Novel Paradigm for Heart Failure With Preserved Ejection FractionJournal of the American College of Cardiology, 2013
- Fatty acid binding protein 4 predicts left ventricular mass and longitudinal function in overweight and obese womenHeart, 2013
- Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studiesEuropean Heart Journal, 2012
- Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAmerican Heart Journal, 2011
- FGF23 induces left ventricular hypertrophyJCI Insight, 2011
- Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection FractionCirculation: Heart Failure, 2011
- The Vascular Marker Soluble Fms-Like Tyrosine Kinase 1 Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart FailureJournal of the American College of Cardiology, 2011
- Serum Adipocyte Fatty Acid-Binding Protein Levels Were Independently Associated With Carotid AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- The Product Space Conditions the Development of NationsScience, 2007